XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Home
Menu

Haematology - Multiple Myeloma

A LIST OF OUR EARLY PHASE Haematology (Multiple myeloma) TRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALS

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

 

GRACE (BP42233)

An Open-Label, Multicenter, Phase I Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7425781 In Participants With Relapsed Or Refractory Multiple Myeloma

Local Project Reference:137532
Principal Investigator:Dr. Rakesh Popat
Drug Class/ Treatment:RO7425781 (T-Cell Engager against GPR5CD)
Escalating dose of RO7425781
Patient Population:Relapsed or Refractory Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

MAJESTEC-2 (64007957MMY1004)

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma

Local Project Reference:137973
Principal Investigator:Dr. Rakesh Popat
Drug Class/ Treatment:Teclistamab (T-Cell Engager targeting BCMA) 
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

MAGNETISMM-9

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (MagnetisMM-9)

Local Project Reference:140976
Principal Investigator:Dr. Rakesh Popat
Drug Class/ Treatment:Elranatamab (B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule)
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

ProMMise

A Platform trial for Relapsed patients to evaluate Ongoing novel therapies in Multiple Myeloma In combination with Standard of care therapies

Local Project Reference:134457
Principal Investigator:Dr. Rakesh Popat
Drug Class/ Treatment:Benlantamab Mafodotin (Anti-BCMA IgG1 Antibody-Drug Conjugate)
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

MonumenTAL-2

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma

Local Project Reference:145605
Principal Investigator:Dr. Rakesh Popat
Drug Class/ Treatment:Talquetamab (T-Cell Redirecting Bispecific Antibody targeting GPRC5D and CD3)
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

DTP3

Treating Multiple Myeloma and Diffuse Large B Cell Lymphoma by Targeting the NFκB Pathway with the First-in-Class GADD45β/MKK7 Inhibitor, DTP3

Local Project Reference:145878
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:

DTP3 (GADD45β/MKK7 Inhibitor)

Dose Escalation Phase

Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

79635322MMY1001

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

Local Project Reference:151562
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:

JNJ-79635322 - CD3 Receptor x BCMA x GPRC5D Trispecific Antibody

Patient Population:Multiple Myeloma